Study to investigate the safety and tolerability of intravenous infusion of a combination of the EpCAM-antibody adecatumumab and docetaxel in patients with EpCAM-positive relapsed or primary refractory advanced stage breast cancer

Sponsor ID

MT201-102

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 1

Product

N/A

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.